MedTrace Logo

A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200

NCT05160389 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-01-27

No results posted yet for this study

Summary

This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.

Conditions

  • Food Effect in Healthy Volunteers

Interventions

DRUG

PBI-200

Single dose of PBI-200

Sponsors & Collaborators

  • Pyramid Biosciences

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Pyramid Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2022-01-06
Completion
2022-01-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160389 on ClinicalTrials.gov